Phase (Ph) I/II study of investigational Aurora A kinase (AAK) inhibitor MLN8237 (alisertib): Updated ph II results in patients (pts) with small cell lung cancer (SCLC), non-SCLC (NSCLC), breast cancer (BrC), head and neck squamous cell carcinoma (HNSCC), and gastroesophageal cancer (GE).
Bohuslav Melichar
Consultant or Advisory Role - Roche
Honoraria - Novartis; Roche
Antoine Adenis
Consultant or Advisory Role - Amgen; Bayer; Roche; Sanofi
Honoraria - Amgen; Bayer; Roche
Libor Havel
No relevant relationships to disclose
Albert C. Lockhart
Research Funding - Millennium
Jaafar Bennouna
Consultant or Advisory Role - Amgen; Roche; Sanofi
Honoraria - Amgen
Claudia Schusterbauer
Employment or Leadership Position - Millennium
Claudio Dansky Ullmann
Employment or Leadership Position - Millennium
Bin Zhang
Employment or Leadership Position - Millennium
Stock Ownership - Takeda
Ely Benaim
Employment or Leadership Position - Millennium
Stock Ownership - Takeda
Elizabeth Claire Dees
Research Funding - Millennium